162 related articles for article (PubMed ID: 33775753)
1. Evaluation of transduced dendritic cells expressing HIV-1 p24-Nef antigens in HIV-specific cytotoxic T cells induction as a therapeutic candidate vaccine.
Sadat Larijani M; Ramezani A; Mashhadi Abolghasem Shirazi M; Bolhassani A; Pouriayevali MH; Shahbazi S; Sadat SM
Virus Res; 2021 Jun; 298():198403. PubMed ID: 33775753
[TBL] [Abstract][Full Text] [Related]
2. In Silico Design and Immunologic Evaluation of HIV-1 p24-Nef Fusion Protein to Approach a Therapeutic Vaccine Candidate.
Larijani MS; Sadat SM; Bolhassani A; Pouriayevali MH; Bahramali G; Ramezani A
Curr HIV Res; 2018; 16(5):322-337. PubMed ID: 30605062
[TBL] [Abstract][Full Text] [Related]
3. Production of Recombinant HIV-1 p24-Nef Protein in Two Forms as Potential Candidate Vaccines in Three Vehicles.
Larijani MS; Pouriayevali MH; Sadat SM; Ramezani A
Curr Drug Deliv; 2020; 17(5):387-395. PubMed ID: 32183667
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 p24-nef DNA Vaccine Plus Protein Boost Expands T-Cell Responses in BALB/c.
Larijani MS; Sadat SM; Bolhassani A; Khodaie A; Pouriayevali MH; Ramezani A
Curr Drug Deliv; 2021; 18(7):1014-1021. PubMed ID: 33388019
[TBL] [Abstract][Full Text] [Related]
5. In vivo delivery of a multiepitope peptide and Nef protein using novel cell-penetrating peptides for development of HIV-1 vaccine candidate.
Davoodi S; Bolhassani A; Namazi F
Biotechnol Lett; 2021 Mar; 43(3):547-559. PubMed ID: 33386500
[TBL] [Abstract][Full Text] [Related]
6. ELISPOT analysis of a new CTL based DNA vaccine for HIV-1 using GM-CSF in DNA prime/peptide boost strategy: GM-CSF induced long-lived memory responses.
Mahdavi M; Ebtekar M; Khorram Khorshid HR; Azadmanesh K; Hartoonian C; Hassan ZM
Immunol Lett; 2011 Oct; 140(1-2):14-20. PubMed ID: 21679728
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Efficacy of HIV-1 Nef-Tat-Gp160-p24 Polyepitope Vaccine Candidate with Nef Protein in Different Immunization Strategies.
Namazi F; Davoodi S; Bolhassani A
Curr Drug Deliv; 2022; 19(1):142-156. PubMed ID: 33655833
[TBL] [Abstract][Full Text] [Related]
8. Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses.
Velashjerdi Farahani S; Reza Aghasadeghi M; Memarnejadian A; Faezi S; Shahosseini Z; Mahdavi M
Pathog Glob Health; 2016 Mar; 110(2):39-47. PubMed ID: 26403975
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a new HIV-1 DNA construct in a BALB/c mouse model.
Mahdavi M; Ebtekar M; Mahboudi F; Khorram Khorshid H; Rahbarizadeh F; Azadmanesh K; Darabi H; Pourasgari F; Hassan ZM
Iran J Immunol; 2009 Dec; 6(4):163-73. PubMed ID: 20054104
[TBL] [Abstract][Full Text] [Related]
10. Engineered dendritic cells-derived exosomes harboring HIV-1 Nef
Pordanjani PM; Bolhassani A; Pouriayevali MH; Milani A; Rezaei F
Int J Biol Macromol; 2024 Jun; 270(Pt 2):132236. PubMed ID: 38768924
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 Gag p24-Nef fusion peptide induces cellular and humoral immune response in a mouse model.
Mahdavi M; Ebtekar M; Azadmanesh K; Khorramkhorshid HR; Rahbarizadeh F; Yazdi MH; Zabihollahi R; Abolhassani M; Hassan ZM
Acta Virol; 2010; 54(2):131-6. PubMed ID: 20545443
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of chloroplast-derived HIV-1 p24 and a p24-Nef fusion protein following subcutaneous and oral administration in mice.
Gonzalez-Rabade N; McGowan EG; Zhou F; McCabe MS; Bock R; Dix PJ; Gray JC; Ma JK
Plant Biotechnol J; 2011 Aug; 9(6):629-38. PubMed ID: 21443546
[TBL] [Abstract][Full Text] [Related]
13. Immune responses against a new HIV-1 p24-gp41/pCAGGS-IL-12 DNA vaccine in Balb/c mice.
Roodbari F; Sabahi F; Sarbolouki MN; Barkhordari F; Adeli A; Jamedar A; Mahboudi F
Iran J Immunol; 2012 Jun; 9(2):86-97. PubMed ID: 22735796
[TBL] [Abstract][Full Text] [Related]
14. Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice.
Wang J; Shu T; Deng W; Zheng Y; Liao M; Ye X; Han L; He P; Zheng X; Li T; Feng Y; Hu F; Li P; Sun C; Chen L; Li F; Feng L
J Virol; 2021 May; 95(12):. PubMed ID: 33789991
[TBL] [Abstract][Full Text] [Related]
15. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
[TBL] [Abstract][Full Text] [Related]
16. Small heat shock protein 27: An effective adjuvant for enhancement of HIV-1 Nef antigen-specific immunity.
Milani A; Bolhassani A; Shahbazi S; Motevalli F; Sadat SM; Soleymani S
Immunol Lett; 2017 Nov; 191():16-22. PubMed ID: 28917624
[TBL] [Abstract][Full Text] [Related]
17. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
[TBL] [Abstract][Full Text] [Related]
18. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization.
Tobery TW; Siliciano RF
J Exp Med; 1997 Mar; 185(5):909-20. PubMed ID: 9120397
[TBL] [Abstract][Full Text] [Related]
19. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.
Blazevic V; Männik A; Malm M; Sikut R; Valtavaara M; Toots U; Ustav M; Krohn K
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):667-77. PubMed ID: 16831091
[TBL] [Abstract][Full Text] [Related]
20. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
